Trogenix

University of Edinburgh spinout Trogenix has secured £70 million in a Series A funding round to advance its innovative cancer therapies into clinical trials. The investment will accelerate the development of treatments for aggressive solid tumours, beginning with glioblastoma, one of the deadl